Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation

Standard

Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. / Kelly, Debra Lynch; Buchbinder, David; Duarte, Rafael F; Auletta, Jeffrey J; Bhatt, Neel; Byrne, Michael; DeFilipp, Zachariah; Gabriel, Melissa; Mahindra, Anuj; Norkin, Maxim; Schoemans, Helene; Shah, Ami J; Ahmed, Ibrahim; Atsuta, Yoshiko; Basak, Grzegorz W; Beattie, Sara; Bhella, Sita; Bredeson, Christopher; Bunin, Nancy; Dalal, Jignesh; Daly, Andrew; Gajewski, James; Gale, Robert Peter; Galvin, John; Hamadani, Mehdi; Hayashi, Robert J; Adekola, Kehinde; Law, Jason; Lee, Catherine J; Liesveld, Jane; Malone, Adriana K; Nagler, Arnon; Naik, Seema; Nishihori, Taiga; Parsons, Susan K; Scherwath, Angela; Schofield, Hannah-Lise; Soiffer, Robert; Szer, Jeff; Twist, Ida; Warwick, Anne; Wirk, Baldeep M; Yi, Jean; Battiwalla, Minoo; Flowers, Mary E; Savani, Bipin; Shaw, Bronwen E.

In: BIOL BLOOD MARROW TR, Vol. 24, No. 2, 02.2018, p. 228-241.

Research output: SCORING: Contribution to journalSCORING: Review articleResearch

Harvard

Kelly, DL, Buchbinder, D, Duarte, RF, Auletta, JJ, Bhatt, N, Byrne, M, DeFilipp, Z, Gabriel, M, Mahindra, A, Norkin, M, Schoemans, H, Shah, AJ, Ahmed, I, Atsuta, Y, Basak, GW, Beattie, S, Bhella, S, Bredeson, C, Bunin, N, Dalal, J, Daly, A, Gajewski, J, Gale, RP, Galvin, J, Hamadani, M, Hayashi, RJ, Adekola, K, Law, J, Lee, CJ, Liesveld, J, Malone, AK, Nagler, A, Naik, S, Nishihori, T, Parsons, SK, Scherwath, A, Schofield, H-L, Soiffer, R, Szer, J, Twist, I, Warwick, A, Wirk, BM, Yi, J, Battiwalla, M, Flowers, ME, Savani, B & Shaw, BE 2018, 'Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation', BIOL BLOOD MARROW TR, vol. 24, no. 2, pp. 228-241. https://doi.org/10.1016/j.bbmt.2017.09.004

APA

Kelly, D. L., Buchbinder, D., Duarte, R. F., Auletta, J. J., Bhatt, N., Byrne, M., DeFilipp, Z., Gabriel, M., Mahindra, A., Norkin, M., Schoemans, H., Shah, A. J., Ahmed, I., Atsuta, Y., Basak, G. W., Beattie, S., Bhella, S., Bredeson, C., Bunin, N., ... Shaw, B. E. (2018). Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. BIOL BLOOD MARROW TR, 24(2), 228-241. https://doi.org/10.1016/j.bbmt.2017.09.004

Vancouver

Bibtex

@article{c7486d55fd6d4700b077b5b310352677,
title = "Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation",
abstract = "Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.",
keywords = "Journal Article, Review",
author = "Kelly, {Debra Lynch} and David Buchbinder and Duarte, {Rafael F} and Auletta, {Jeffrey J} and Neel Bhatt and Michael Byrne and Zachariah DeFilipp and Melissa Gabriel and Anuj Mahindra and Maxim Norkin and Helene Schoemans and Shah, {Ami J} and Ibrahim Ahmed and Yoshiko Atsuta and Basak, {Grzegorz W} and Sara Beattie and Sita Bhella and Christopher Bredeson and Nancy Bunin and Jignesh Dalal and Andrew Daly and James Gajewski and Gale, {Robert Peter} and John Galvin and Mehdi Hamadani and Hayashi, {Robert J} and Kehinde Adekola and Jason Law and Lee, {Catherine J} and Jane Liesveld and Malone, {Adriana K} and Arnon Nagler and Seema Naik and Taiga Nishihori and Parsons, {Susan K} and Angela Scherwath and Hannah-Lise Schofield and Robert Soiffer and Jeff Szer and Ida Twist and Anne Warwick and Wirk, {Baldeep M} and Jean Yi and Minoo Battiwalla and Flowers, {Mary E} and Bipin Savani and Shaw, {Bronwen E}",
note = "Copyright {\textcopyright} 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.bbmt.2017.09.004",
language = "English",
volume = "24",
pages = "228--241",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation

AU - Kelly, Debra Lynch

AU - Buchbinder, David

AU - Duarte, Rafael F

AU - Auletta, Jeffrey J

AU - Bhatt, Neel

AU - Byrne, Michael

AU - DeFilipp, Zachariah

AU - Gabriel, Melissa

AU - Mahindra, Anuj

AU - Norkin, Maxim

AU - Schoemans, Helene

AU - Shah, Ami J

AU - Ahmed, Ibrahim

AU - Atsuta, Yoshiko

AU - Basak, Grzegorz W

AU - Beattie, Sara

AU - Bhella, Sita

AU - Bredeson, Christopher

AU - Bunin, Nancy

AU - Dalal, Jignesh

AU - Daly, Andrew

AU - Gajewski, James

AU - Gale, Robert Peter

AU - Galvin, John

AU - Hamadani, Mehdi

AU - Hayashi, Robert J

AU - Adekola, Kehinde

AU - Law, Jason

AU - Lee, Catherine J

AU - Liesveld, Jane

AU - Malone, Adriana K

AU - Nagler, Arnon

AU - Naik, Seema

AU - Nishihori, Taiga

AU - Parsons, Susan K

AU - Scherwath, Angela

AU - Schofield, Hannah-Lise

AU - Soiffer, Robert

AU - Szer, Jeff

AU - Twist, Ida

AU - Warwick, Anne

AU - Wirk, Baldeep M

AU - Yi, Jean

AU - Battiwalla, Minoo

AU - Flowers, Mary E

AU - Savani, Bipin

AU - Shaw, Bronwen E

N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.

AB - Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.

KW - Journal Article

KW - Review

U2 - 10.1016/j.bbmt.2017.09.004

DO - 10.1016/j.bbmt.2017.09.004

M3 - SCORING: Review article

C2 - 28939455

VL - 24

SP - 228

EP - 241

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 2

ER -